Literature DB >> 10365298

Extensor supracondylar femoral osteotomy as treatment for flexed haemophilic knee.

H A Caviglia1, R Perez-Bianco, G Galatro, C Duhalde, M Tezanos-Pinto.   

Abstract

The experience with extensor supracondylar femoral osteotomy as treatment for the flexed haemophilic knee is presented with the description of 19 patients treated during a 30-year period (1968-98). The average age of the patients was 16 (8-35 years), and the average age follow-up was 13 years (3-30 years). Six patients had flexion fixed deformity while the rest presented 40 degrees average range of motion (10-75 degrees). In 13 patients a single osteotomy without internal fixation was performed, in one an osteosynthesis with a condylar plate and in five stabilization was achieved by means of Blount staples. Previous surgery was performed in two patients with patello-femoral ankylosis. The osteotomy site was consolidated in every patient and the deformity was corrected. Two bleeding complications were observed: one haemarthrosis and one psoas haematoma. Flexion relapsed in one patient who underwent another procedure after 12 years. One patient presented with a peroneal nerve paralysis; another one a genu recurvartum; which required flexor osteotomy. The extensor supracondylar femoral osteotomy is a procedure that aligns the limb with scarce modification of articular mobility.

Entities:  

Mesh:

Year:  1999        PMID: 10365298     DOI: 10.1046/j.1365-2516.1999.0050s1028.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

Review 1.  Orthopedic disorders of the knee in hemophilia: A current concept review.

Authors:  E Carlos Rodriguez-Merchan; Leonard A Valentino
Journal:  World J Orthop       Date:  2016-06-18

2.  Outcome of osteotomies for the treatment of haemophilic arthropathy of the knee.

Authors:  K Trieb; J Panotopoulos; H Hartl; W Brodner; I Pabinger; A Wanivenhaus
Journal:  Langenbecks Arch Surg       Date:  2003-11-14       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.